Evidence map›Paper›PMID 42548692›Full record

ReviewFrontiers in microbiology2026

Resistance breakers: a novel approach to tackle biofilm associated infections and antimicrobial resistance.

Zangini Nakazwe, Simone Ries, Sanchita Kar, Mitali Sarkar-Tyson, Aleksandra W Debowski, Ethan Haese, Keith A Stubbs, Maud Eijkenboom, K Swaminathan-Iyer, Andrew Barker

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zangini NakazweThe Department of Chemistry, School of Molecular Sciences, The University of Western Australia, Perth, WA, Australia.
Simone RiesThe Department of Chemistry, School of Molecular Sciences, The University of Western Australia, Perth, WA, Australia.
Sanchita KarThe Department of Chemistry, School of Molecular Sciences, The University of Western Australia, Perth, WA, Australia.
Mitali Sarkar-TysonThe Marshall Centre for Infectious Disease Research and Training, School of Biomedical Sciences, The University of Western Australia, Perth, WA, Australia.
Aleksandra W DebowskiThe Department of Chemistry, School of Molecular Sciences, The University of Western Australia, Perth, WA, Australia.
Ethan HaeseLixa Ltd., Perth, WA, Australia.
Keith A StubbsThe Department of Chemistry, School of Molecular Sciences, The University of Western Australia, Perth, WA, Australia.
Maud EijkenboomLixa Ltd., Perth, WA, Australia.
K Swaminathan-IyerThe Department of Chemistry, School of Molecular Sciences, The University of Western Australia, Perth, WA, Australia.
Andrew BarkerThe Marshall Centre for Infectious Disease Research and Training, School of Biomedical Sciences, The University of Western Australia, Perth, WA, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) has emerged as one of the greatest global health concerns and its threat to effective treatment of infectious diseases is accelerating. Biofilms remain a major contributor to antimicrobial resistance and persistence of infections. Bacterial biofilms are sessile communities of bacteria surrounded by a self-produced extracellular polymeric substance (EPS). Bacterial cells in biofilms are less susceptible to conventional antibiotics and to host immune effector mechanisms as the cells are protected by the EPS, exhibit altered gene expression as well as heterogeneity in metabolic and physiological states compared to planktonic cells. This poses a challenge for antimicrobial treatments and the development of innovative antibiofilm strategies to combat biofilm associated infections and resistance. This review explores resistance in bacterial biofilms and the recent advancements in resistance breakers: compounds that can inhibit or disrupt mechanisms of resistance to restore clinical efficacy of antibiotics. Different categories of resistance breakers are discussed including matrix disruptors, efflux pump inhibitors, enzyme inhibitors, membrane permeabilizers, quorum sensing inhibitors, and metabolic modulators. Finally, we discuss perspectives on existing translational and clinical challenges.

Indexed as

antibiofilm strategiesantimicrobial resistanceantimicrobial synergybiofilmscombination therapyresistance breakers

Identifiers

PMID42548692
PMCPMC13429720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.